Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | GPR3 | P46089 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29972693 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2CYP2C9CYP17A1CYP2C19KDM4E | |
| SCHEMBL17717291 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2CYP2C9CYP17A1CYP2C19MAPT | |
| SCHEMBL24683493 | 0.83 | CYP2C9 (0.49) | SMN1; SMN2CYP2C9CYP17A1CYP2C19KDM4E | |
| SCHEMBL12578461 | 0.81 | SMN1; SMN2 (0.49) | SMN1; SMN2MAPTLMNAALOX15TSHR | |
| SCHEMBL29972592 | 0.80 | KDM4E (0.45) | SMN1; SMN2CYP2C9CYP17A1CYP2C19KDM4E | |
| SCHEMBL23977879 | 0.80 | CYP2C9 (0.46) | SMN1; SMN2CYP2C9CYP17A1CYP2C19KDM4E | |
| SCHEMBL14937673 | 0.80 | KDM4E (0.45) | SMN1; SMN2CYP2C9CYP17A1CYP2C19KDM4E | |
| SCHEMBL23414843 | 0.80 | KDM4E (0.45) | SMN1; SMN2CYP2C9CYP17A1CYP2C19KDM4E | |
| SCHEMBL2031055 | 0.80 | ALDH1A1 (0.55) | SMN1; SMN2CYP2C9CYP17A1CYP2C19KDM4E | |
| SCHEMBL25405284 | 0.79 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1MAPTLMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479844-B2 | Ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | AMGEN INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250145637-A1 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| EP-4385989-A1 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2024-06-19 | — | — | EP | disclosed |
| CN-117597341-A | Sulfonamide derivative, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| WO-2023016484-A1 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2023-02-16 | — | — | WO | disclosed |
| WO-2023016484-A1 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2023-02-16 | — | — | WO | disclosed |
| EP-4065579-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| US-20210403476-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-12-30 | — | — | US | disclosed |
| CN-113573713-A | Ion channel modulators | 普拉克西斯精密药物股份有限公司 | 2021-10-29 | — | — | CN | disclosed |
| WO-2021108404-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| WO-2020069322-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| EP-2079674-B1 | PROCESS FOR THE PREPARATION OF TRIFLUOROETHOXYTOLUENES | GRINDEKS JSC (LV) | 2011-06-29 | — | — | EP | disclosed |
| US-20100063292-A1 | PROCESS FOR THE PREPARATION OF TRIFLUOROETHOXYTOLUENES. | GRINDEKS A JOINT STOCK COMPANY (LV) | 2010-03-11 | — | — | US | disclosed |
| US-20100056794-A1 | PROCESS FOR THE PREPARATION OF 2,5-BIS-(2,2,2-TRIFLUOROETHOXY)-N-(2-PIPERIDYL-METHYL)-BENZAMIDE AND SALTS THEREOF | GRINDEKS A JOINT STOCK COMPANY (LV) | 2010-03-04 | — | — | US | disclosed |
| EP-2079674-A1 | PROCESS FOR THE PREPARATION OF TRIFLUOROETHOXYTOLUENES | Grindeks, a joint stock company (LV) | 2009-07-22 | — | — | EP | disclosed |
| EP-2079692-A1 | PROCESS FOR THE PREPARATION OF 2,5-BIS-(2,2,2-TRIFLUOROETHOXY)-N-(2-PIPERIDYLMETHYL)-BENZAMIDE AND SALTS THEREOF | Grindeks, a joint stock company (LV) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008055849-A1 | PROCESS FOR THE PREPARATION OF TRIFLUOROETHOXYTOLUENES | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008055851-A1 | PROCESS FOR THE PREPARATION OF 2,5-BIS-(2,2,2-TRIFLUOROETHOXY)-N-(2-PIPERIDYLMETHYL)-BENZAMIDE AND SALTS THEREOF | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2008-05-15 | — | — | WO | disclosed |
| EP-1918280-A1 | Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)-benzamide and salts thereof | "Joint Stock Company Grindeks" (LV) | 2008-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403476-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | SMN1; SMN2 185/4885CYP2C9 3258/4885CYP17A1 4316/4885 |
| US-20100056794-A1 | PROCESS FOR THE PREPARATION OF 2,5-BIS-(2,2,2-TRIFLUOROETHOXY)-N-(2-PIPERIDYL-METHYL)-BENZAMIDE AND SALTS THEREOF | BOLA2; BOLA2B, TET2, CYP1A2 | SMN1; SMN2 1097/4885CYP2C9 181/4885CYP17A1 1481/4885 |
| US-20250145637-A1 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SULT2A1, KAT8, TST | SMN1; SMN2 4679/4885CYP2C9 648/4885CYP17A1 408/4885 |
| US-12479844-B2 | Ion channel modulators | SCN1A, SCN3A, SCN2A | SMN1; SMN2 185/4885CYP2C9 3258/4885CYP17A1 4316/4885 |
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | SCD5, SCD, FADS2 | SMN1; SMN2 3098/4885CYP2C9 116/4885CYP17A1 320/4885 |
| US-20100063292-A1 | PROCESS FOR THE PREPARATION OF TRIFLUOROETHOXYTOLUENES. | CYP2C9, CYP3A4, CYP3A5 | SMN1; SMN2 1342/4885CYP2C9 1/4885CYP17A1 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.